AAPL 222.805 0.5755% MSFT 389.91 -0.0154% NVDA 112.0884 -1.4694% GOOGL 163.3 -1.0663% GOOG 165.2581 -1.1259% AMZN 201.735 0.3008% META 606.4272 -0.7452% AVGO 171.95 -4.0832% LLY 817.515 -1.1182% TSLA 277.69 2.0694% TSM 167.79 -3.2911% V 349.7225 1.6103% JPM 248.33 -1.0756% UNH 513.78 -0.853% NVO 70.075 -2.3073% WMT 85.475 0.311% LVMUY 126.98 0.063% XOM 118.11 -0.1353% LVMHF 636.5 0.2141% MA 561.135 2.1974%
AAPL 222.805 0.5755% MSFT 389.91 -0.0154% NVDA 112.0884 -1.4694% GOOGL 163.3 -1.0663% GOOG 165.2581 -1.1259% AMZN 201.735 0.3008% META 606.4272 -0.7452% AVGO 171.95 -4.0832% LLY 817.515 -1.1182% TSLA 277.69 2.0694% TSM 167.79 -3.2911% V 349.7225 1.6103% JPM 248.33 -1.0756% UNH 513.78 -0.853% NVO 70.075 -2.3073% WMT 85.475 0.311% LVMUY 126.98 0.063% XOM 118.11 -0.1353% LVMHF 636.5 0.2141% MA 561.135 2.1974%

Low Carbon Research Report

Medibank Private Limited

Nov 22, 2024

MPL:ASX
Investment Type
Large-cap
Risk Level
Action
Rec. Price (AU$)

This report is an updated version of the report published on 22 November 2024 at 03:48 PM AEDT.

Section 1: Company Overview, Low Carbon Emission Initiatives and Fundamentals

Section 1.1: Medibank Private Limited (ASX: MPL) is an integrated healthcare company that provides private health insurance and health solutions in Australia. MPL also offers other insurance, including travel, pet, and life insurance, to make things easier for its customers. Kalkine’s Low Carbon Research Report covers the Investment Highlights, Low Carbon Emission Initiatives, Key Financial Metrics, Risks, and Technical Analysis along with the Valuation, Target Price, and Recommendation on the stock.

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Copyright © 2024 Krish Capital Pty Ltd. All rights reserved.